The CHARM program: study design leads to findings of clinical and public health importance

In large-scale randomized trials and their meta-analyses, beta-adrenergic blockers and angiotensin-converting enzyme inhibitors provide statistically significant and clinically important additive mortality and morbidity benefits in the treatment of heart failure. The CHARM trials were designed to test whether the angiotensin-receptor blocker candesartan would provide statistically significant and clinically important additive mortality and morbidity benefits to patients with heart failure as an alternative or in addition to angiotensin-converting enzyme inhibitors. CHARM demonstrated that an angiotensin-receptor blocker at a proven dose is an effective and safe therapy as an alternative or in addition to angiotensin-converting enzyme inhibitors in patients with heart failure, 55% of whom were receiving beta-adrenergic blockers. These benefits include reductions in cardiovascular mortality rate as well as in hospitalization for heart failure. Such patients have a 50% mortality rate at 5 years, and heart failure is the leading cause of hospitalization for patients 65 years of age and older.

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kardiologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cardiac and Cardiovascular Systems hsv//eng
Adrenergic beta-Antagonists
Aged
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/therapeutic use
Benzimidazoles/*therapeutic use
Cardiac Output
Low/*drug therapy/mortality
Drug Therapy
Combination
Hospitalization
Humans
Meta-Analysis as Topic
Randomized Controlled Trials as Topic
Tetrazoles/*therapeutic use

Pfeffer, M. A. (författare)
Swedberg, Karl,1944Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine(Swepub:gu)xsweka (författare)
Göteborgs universitetInstitutionen för medicin, avdelningen för akut och kardiovaskulär medicin (creator_code:org_t)

Ingår i:J Cardiovasc Pharmacol Ther: SAGE Publications12:2, s. 124-61074-2484
Ingår i:Journal of Cardiovascular Pharmacology and Therapeutics: SAGE Publications12:2, s. 124-61940-4034

Av författaren/redakt...: Hennekens, C. H.; Pfeffer, M. A.; Swedberg, Karl, ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kardiologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.